0001181431-12-065789.txt : 20121218
0001181431-12-065789.hdr.sgml : 20121218
20121218200857
ACCESSION NUMBER: 0001181431-12-065789
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20121217
FILED AS OF DATE: 20121218
DATE AS OF CHANGE: 20121218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PHILLIPS RICHARD BENTON
CENTRAL INDEX KEY: 0001433384
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35703
FILM NUMBER: 121272871
MAIL ADDRESS:
STREET 1: 10990 WILSHIRE BOULEVARD
STREET 2: SUITE 1200
CITY: LOS ANGELES
STATE: MN
ZIP: 90024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC.
CENTRAL INDEX KEY: 0001401667
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770683487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: (424) 248-6500
MAIL ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP
DATE OF NAME CHANGE: 20070601
4
1
rrd363889.xml
PHILLIPS F4
X0306
4
2012-12-17
0
0001401667
PUMA BIOTECHNOLOGY, INC.
PBYI
0001433384
PHILLIPS RICHARD BENTON
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES
CA
90024
0
1
0
0
SEE REMARKS
Stock Option (Right to Buy)
19.34
2012-12-17
4
A
0
31500
0
A
2022-12-17
Common Stock
31500
31500
D
The vesting commencement date ("Vesting Commencement Date") of the option is December 17, 2012. The option vests (i) with respect to one-third (1/3rd) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares of the underlying option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer.
Title of Reporting Person: Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance
/s/ Richard B. Phillips
2012-12-18